Compare Gilead Sciences, Inc. (GILD) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Stanley Black & Decker, Inc. — how do they compare? Gilead Sciences, Inc. trades at $136.66 (market cap $168.35B), while Stanley Black & Decker, Inc. trades at $102.3 (market cap $15.71B). The key difference: Gilead Sciences, Inc. is far larger — about 10.7× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals.
| GILD | SWK | |
|---|---|---|
Market Cap | $168.35B | $15.71B |
Sector | Health | — |
52-Week High | $155.80 | $104.00 |
52-Week Low | $110.56 | $62.12 |
Enterprise Value | $191.42B | $19.87B |
Dividend Yield | 2.42% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Stanley Black & Decker (SWK) trades at $102.64, down 1.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.57 versus $1.21 expected, driven by margin expansion and strong organic growth. The company announced a $1 billion U.S. investment plan to boost manufacturing and innovation, signaling strategic growth commitment.
The outlook is positive with improving profitability and debt reduction, but risks include competitive pressures and economic sensitivity. Analysts are mixed with a $93.67 consensus target below current price, suggesting cautious optimism. Upside hinges on continued execution of cost savings and market share gains in tools and infrastructure sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
